New pill could help dialysis patients fight anemia without needles
NCT ID NCT03461146
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tested an oral drug called vadadustat (MT-6548) in 24 Japanese adults on hemodialysis who had anemia due to chronic kidney disease. The goal was to see if the drug could raise and maintain healthy hemoglobin levels safely. Participants took the tablet daily, and researchers tracked blood counts and side effects over several months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vadadustat (MT-6548), an oral tablet
What this could lead to
If successful, this could offer a new oral option to manage anemia in people on dialysis, potentially reducing the need for injections of erythropoiesis-stimulating agents.
What could go wrong
This is a small, early-phase study in Japan only, so results may not apply broadly. The drug may not work as well as expected or could have side effects like high blood pressure or blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA; HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research site
Aichi, Japan
-
Research site
Chiba, Japan
-
Research site
Fukushima, Japan
-
Research site
Gunma, Japan
-
Research site
Hokkaido, Japan
-
Research site
Hyōgo, Japan
-
Research site
Ibaraki, Japan
-
Research site
Kagoshima, Japan
-
Research site
Nagano, Japan
-
Research site
Okayama, Japan
-
Research site
Okinawa, Japan
-
Research site
Osaka, Japan
-
Research site
Saitama, Japan
-
Research site
Shiga, Japan
-
Research site
Shizuoka, Japan
-
Research site
Yamagata, Japan